Koh Bong Y's Form 4 filing
KalVista Pharmaceuticals, Inc. (KALV) · filed Feb 22, 2024
- Accession no.
- 0001415889-24-004790
- Filed
- Feb 22, 2024, 4:15 PM ET
- Trade date
- Feb 20, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 derivative transaction. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Koh Bong YCIK 0001615979 | 10% Owner |
| Shah Nimish PCIK 0001698082 | 10% Owner |
| Venrock Healthcare Capital Partners III, L.P.CIK 0001738048 | 10% Owner |
| VHCP Management III, LLCCIK 0001738053 | 10% Owner |
| VHCP Co-Investment Holdings III, LLCCIK 0001750761 | 10% Owner |
| Venrock Healthcare Capital Partners EG, L.P.CIK 0001808512 | 10% Owner |
| VHCP Management EG, LLCCIK 0001808518 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 20, 2024 | Common Stock | PPurchaseAcquired | +655,738 | $15.25 | +$9,999,348.76 | 655,738 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.